The latest Herceptin biosimilar is branded as Kanjinti (trastuzumab-anns) and is approved in all indications of the reference product. These are for the treatment of HER2-overexpressing adjuvant ...
Stock gave a 3 year return of 163.56% as compared to Nifty Smallcap 100 which gave a return of 46.33%. (as of last trading session) Stock Returns vs Nifty Pharma Stock generated 163.56% return as ...
After hours: 13 March at 7:20:24 pm GMT-4 Loading Chart for AMGN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback